COLUSSI, Gian Luca
 Distribuzione geografica
Continente #
NA - Nord America 12.884
AS - Asia 5.735
EU - Europa 4.184
SA - Sud America 1.076
AF - Africa 121
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 9
Totale 24.031
Nazione #
US - Stati Uniti d'America 12.724
SG - Singapore 2.835
CN - Cina 1.147
UA - Ucraina 1.128
IT - Italia 859
BR - Brasile 843
HK - Hong Kong 609
DE - Germania 567
FI - Finlandia 432
VN - Vietnam 350
RU - Federazione Russa 292
FR - Francia 259
IE - Irlanda 200
TR - Turchia 164
IN - India 152
SE - Svezia 125
GB - Regno Unito 121
AR - Argentina 98
BD - Bangladesh 92
CA - Canada 87
KR - Corea 70
IQ - Iraq 53
MX - Messico 48
JP - Giappone 39
NL - Olanda 39
PK - Pakistan 37
CO - Colombia 33
EC - Ecuador 29
ZA - Sudafrica 29
BE - Belgio 26
PL - Polonia 26
UZ - Uzbekistan 25
ID - Indonesia 24
AT - Austria 23
MA - Marocco 22
VE - Venezuela 22
EU - Europa 19
ES - Italia 18
IR - Iran 18
SA - Arabia Saudita 18
EG - Egitto 16
CZ - Repubblica Ceca 15
LB - Libano 15
JO - Giordania 14
PE - Perù 14
CL - Cile 13
KE - Kenya 13
DZ - Algeria 9
PY - Paraguay 9
TN - Tunisia 9
CH - Svizzera 8
MY - Malesia 8
OM - Oman 8
AU - Australia 7
BO - Bolivia 7
UY - Uruguay 7
EE - Estonia 6
PH - Filippine 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
CR - Costa Rica 5
NP - Nepal 5
IL - Israele 4
PS - Palestinian Territory 4
RO - Romania 4
RS - Serbia 4
TG - Togo 4
BW - Botswana 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GE - Georgia 3
GR - Grecia 3
HN - Honduras 3
JM - Giamaica 3
KZ - Kazakistan 3
LT - Lituania 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AL - Albania 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BT - Bhutan 2
BZ - Belize 2
CM - Camerun 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
ME - Montenegro 2
MU - Mauritius 2
NI - Nicaragua 2
NO - Norvegia 2
PA - Panama 2
QA - Qatar 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 24.005
Città #
Woodbridge 1.428
Singapore 1.194
Fairfield 1.110
Ashburn 927
Ann Arbor 912
Jacksonville 798
Hong Kong 607
San Jose 605
Chandler 594
Houston 581
Beijing 543
Dearborn 501
Wilmington 496
Seattle 456
Cambridge 370
Boardman 282
Council Bluffs 219
Princeton 217
Dublin 198
Lauterbourg 197
Los Angeles 160
Udine 150
Buffalo 109
Izmir 109
Dallas 101
Hefei 91
Ho Chi Minh City 88
San Diego 84
Hanoi 82
Helsinki 75
São Paulo 67
New York 64
Seoul 60
Redondo Beach 59
The Dalles 58
Des Moines 50
Munich 50
Ogden 48
Dong Ket 47
Milan 45
Norwalk 44
Santa Clara 44
Redmond 42
Ottawa 40
Nanjing 37
Tokyo 37
Orem 36
Mumbai 35
Frankfurt am Main 33
Rome 33
San Mateo 32
Kunming 30
Rio de Janeiro 29
Nuremberg 28
Baghdad 26
Brussels 26
Guangzhou 26
Atlanta 24
Warsaw 24
Pittsburgh 23
Belo Horizonte 22
Brooklyn 21
London 21
Johannesburg 20
Phoenix 20
Tashkent 20
Amsterdam 19
Ankara 19
Trieste 19
Chennai 18
Dhaka 18
Shanghai 18
Chicago 17
San Francisco 17
Stockholm 17
Denver 16
Manchester 15
Montreal 15
Goiânia 14
Vienna 14
Boston 13
Mcallen 13
New Delhi 13
Amman 12
Brasília 12
Brno 12
Grafing 12
Jinan 12
Nairobi 12
Poplar 12
Porto Alegre 12
Cairo 11
Da Nang 11
Falls Church 11
Fortaleza 11
Mexico City 11
Quito 11
Turku 11
Washington 11
Bologna 10
Totale 15.074
Nome #
Decreased fibrinolytic activity is associated with carotid artery stiffening in arterial hypertension 270
Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies 243
Aldosterone and the heart: from basic research to clinical evidence 206
Aldosterone and Left Ventricular Remodeling 198
Early renal failure as a cardiovascular disease: Focus on lipoprotein(a) and prothrombotic state 184
Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: relevance for cardiovascular outcomes 182
Aldosterone and the heart: still an unresolved issue? 180
Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease 178
Aldosterone, Organ Damage, and Dietary Salt 173
Cellular mechanisms of insulin resistance in rats with fructose-induced hypertension 172
Long-Term Renal and Cardiac Outcomes after Stenting in Patients with Resistant Hypertension and Atherosclerotic Renal Artery Stenosis 171
Role of Aldosterone in Insulin Resistance: Fact of Fantasy 169
Relationships of plasma renin levels with renal function in patients with primary aldosteronism 166
Vasculite dei vasa-nervorum: risposta alla terapia immunosoppressiva. Case Report 166
Benzodiazepines regulate the vascular tone vie an endothelium-independent mechanism 165
Pre-Procedural Statin Use Is Associated with Improved Long-Term Survival and Reduced Major Cardiovascular Events in Patients Undergoing Carotid Artery Stenting: A Retrospective Study 162
Editorial comment from Dr Catena, Dr Colussi, and Dr Sechi to preoperative masse renal damage in japanese patients with primry aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. 161
Diabetes, diabetic complications, and blood pressure targets 160
Moderate alcohol consumption is associated with left ventricular diastolic dysfunction in nonalcoholic hypertensive patients 160
Fish Meal Supplementation and Ambulatory Blood Pressure in Patients With Hypertension: Relevance of Baseline Membrane Fatty Acid Composition 159
Salt, Aldosterone, and Parathyroid Hormone: What Is the Relevance for Organ Damage? 157
Relationship of Plasma Renin With a Prothrombotic State in Hypertension: Relevance for Organ Damage 157
Treatment of primary aldosteronism and organ protection 157
A Prothrombotic State is Associated with Early Arterial Damage in Hypertensive Patients 156
The emergent cardiovascular risk factors and organ damage in arterial hypertension 155
Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 155
Elevated homocysteine levels are associated with the metabolic syndrome and cardiovascular events in hypertensive patients 155
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 153
Intrarenal Vascular Resistance is Associated with a Prothrombotic State in Hypertensive Patients 151
The Metabolic Syndrome and the Membrane Content of Polyunsaturated Fatty Acids in Hypertensive Patients 150
Aldosterone plasmatico e escrezione urinaria di albumina nell’ipertensione arteriosa 149
Salt, hypertension, and cardiovascular disease 149
Elevated Blood Pressure in Children of Cardiovascular Risk Mothers: Could Maternal Folic Acid Be the Link? 149
Cardiovascular outcomes in patients with primary aldosteronism after treatment 149
Omega-3 Polyunsaturated Fatty Acids in the Treatment of Non-Alcoholic Fatty Liver Disease: Are They So Good? 147
A prothrombotic state is associated with increased carotid intima-media thickness in hypertension 145
Benzodiazepines: an old class of new antihypertensive drugs? 145
Glucocorticoid-induced leucine zipper protein regulates sodium and potassium balance in the distal nephron 145
Renal function in primary aldosteronism 143
Involvement of endothelium-dependent and -independent mechanisms in midazolam-induced vasodilation 143
Potassium-sparing diuretics in hypertension 141
Kidney in primary aldosteronism: a key determinant of treatment outcome 141
The vascular response to vasodilators is related to the membrane content of polyunsaturated fatty acids in hypertensive patients 140
Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery? 139
Evaluation of endothelial function in patients with non-alcoholic fatty liver disease 136
Association of Post-Saline Load Plasma Aldosterone Levels with Left Ventricular Hypertrophy in Primary Hypertension 136
Effects of the consumption of fish meals on the carotid IntimaMedia thickness in patients with hypertension: a prospective study 135
Association of aldosterone with left ventricular mass in hypertension: interaction with plasma fibrinogen levels 134
New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a) 134
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società  Italiana di Medicina Interna) Study 134
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension 132
AORTIC STIFFNESS AND INDEXES OF DISEASE SEVERITY IN SUBJECTS WITH PREVIOUS COVID-19 PNEUMONIA: A FOLLOW-UP STUDY 130
ACIDI GRASSI POLIINSATURI OMEGA-3 E FATTORI DI RISCHIO CARDIOVASCOLARE 130
Endothelial function in patients with non-alcoholic fatty liver disease 129
The Rising Burden of Hypertensive Renal Disease in Low-Income Countries: Is it Time to Take Action? 129
Carotid artery stiffness is related to hyperinsulinemia and insulin-resistance in middle-aged, non-diabetic hypertensive patients 129
Hypertension and type 2 diabetes: lights and shadows about causality 129
Atrial fibrillation and its complications in arterial hypertension: The potential preventive role of ω-3 polyunsaturated fatty acids 128
Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis 128
Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment 127
Insulin sensitivity in patients with primary aldosteronism: a follow-up study 127
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 127
Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients 127
Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients 126
Plasma glucose levels and left ventricular diastolic function in nondiabetic hypertensive patients 126
Ambulatory blood pressure and left ventricular geometry in patients with myotonic dystrophy 125
Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new 125
Uricaemia and left ventricular mass in hypertensive patients 125
Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension 124
Renal function in primary aldosteronism: revisiting the concept of “renin escape” 124
Alpha-adducin gene polymorphism predicts cardiac and vascular response to treatment in hypertensive women 123
Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients: Response to Perciaccante et al. [4] 122
Association of elevated levels of PAI-1 with insulin resistance and inflammatory markers in hypertension. 121
Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era 121
Association of a prothrombotic state with the metabolic syndrome in essential hypertensive patients 120
Associazione dell’ispessimento miointimale carotideo con uno stato protrombotico in pazienti ipertesi 120
Response to "plasma Homocysteine Levels and Endothelial Dysfunction in Cerebro-and Cardiovascular Diseases in the Metabolic Syndrome" 120
Abnormal 24-hour blood pressure profile and left ventricular geometry in patients with myotonic dystrophy 120
RELATIONSHIPS BETWEEN NAFLD BIOCHEMICAL SCORES AND LEFT VENTRICULAR GEOMETRIC PATTERN IN NAÏVE ESSENTIAL HYPERTENSIVE PATIENTS 119
Studio della funzione endoteliale in pazienti con steatosi epatica non-alcolica. 119
Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment 119
Plasma lipoprotein(a) levels and atherosclerotic renal artery stenosis in hypertensive patients 119
Cardiac and renal damage in primary aldosteronism 117
Reversal of left ventricular hypertrophy after treatment is related to severity of disease in patients with primary aldosteronism 116
The new cardiovascular risk factors in hypertensive patients with metabolic syndrome 116
The carotid intima-media thickness and cardiac tissue Doppler in hypertension 114
Relationships of plasma renin with renal function in primary aldosteronism: revisiting the concept of renin escape 114
. L’attività fisica migliora la sensibilità all’insulina ed i fattori di rischio protrombotico in una popolazione di pazienti ipertesi 114
Omega-3 polyunsaturated fatty acids in blood pressure control and essential hypertension 114
Mineralocorticoid Antagonists Treatment Versus Surgery in Primary Aldosteronism 113
Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) 113
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 112
Renal and cardiovascular outcomes in renal revascularization in patients with resistant hypertension. 111
Functioning or Non-Functioning Adrenal Adenoma? Probably, Just a Matter of Time 111
Prognostic role of malnutrition diagnosed by bioelectrical impedance vector analysis in older adults hospitalized with covid-19 pneumonia: A prospective study 111
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 110
Effects of n-3 polyunsatured fatty acids (PUFA) on markers of oxidative stress in hypertension 109
Hyperaldosteronism and Left Ventricular Hypertrophy 109
Association of a prothrombotic state with carotid intima-media thickness in hypertensive patients 108
Echocardiographic Comparison of COVID-19 Patients with or without Prior Biochemical Evidence of Cardiac Injury after Recovery 107
Totale 14.014
Categoria #
all - tutte 95.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.993


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021136 0 0 0 0 0 0 0 0 0 0 0 136
2021/20221.596 76 182 64 125 47 55 85 96 22 256 307 281
2022/20231.649 251 95 31 184 139 486 6 92 234 24 55 52
2023/2024520 91 32 41 9 82 58 23 12 70 20 8 74
2024/20253.580 80 265 141 116 72 155 173 186 415 294 638 1.045
2025/20266.825 476 714 543 601 1.065 557 955 225 542 600 442 105
Totale 24.620